Newsmakers: Gilead, Amedisys, Compugen, iCAD, Cara Therapeutics Print E-mail
Wednesday, 29 October 2014 14:12
U.S. stocks dipped and bonds slid after the

Error. Page cannot be displayed. Please contact your service provider for more details. (5)

Federal Reserve offered a brighter assessment of the U.S. job market, a shift that investors reckoned could bring forward the timing of interest-rate increases. The Fed also said it would end its bond-buying program in October, as expected. The Dow Jones Industrial Average was down 35 points, or 0.2%, to 16970, trading near session lows. The S&P 500 fell six points, or 0.3%, to 1978.The Nasdaq Composite declined 25 points, or 0.5%, to 4540.

With doctors and patients waiting for the launch of Gilead's (NASDAQ:GILD) Harvoni hepatitis drug, Q3 Sovaldi sales ($2.8B) fell short of a FactSet consensus of $2.93B.Piper: "GILD reported a somewhat sloppy 3Q, with strong beats for the HIV franchise, particularly products that are facing generic entry over the next 5-7 years, while the HCV franchise that is also being replaced by the new HCV franchise came in weak."

Amedisys Inc(NASDAQ:AMED) Q3 results: Revenues: $300.3M (-0.3%); COGS: $170.2M (-2.9%); Operating Expenses: $284M (-37.7%); Operating Income: $16.2M (+110.5%); Net Income: $8.4M (+109.2%); EPS: $0.26 (+109.0%); Quick Assets: $5.5M (-68.2%); CF Ops: $25.3M (-9.3%).

Compugen Ltd. (USA)(NASDAQ:CGEN) Q3 results: Revenues: $1.7M (+6.2%); Gross Profit: $1M (+900.0%); Operating Expense: $5.6M (+24.4%); Operating Loss: ($4.6M) (-4.5%); Net Loss: ($5.4M) (-14.9%); Loss Per Share: ($0.11) (+8.3%); Quick Assets: $107.4M (+129.5%).

iCAD Inc(NASDAQ:ICAD) Q3 results: Revenues: $12.6M (+51.8%); Gross Profit: $9.2M (+55.9%); Operating Expenses: $7.8M (+30.0%); Operating Income: $0.9M (+325.0%); Net Income: $0.3M (+150.0%); EPS: $0.02 (+140.0%); Quick Assets: $33.4M (+180.7%); CF Ops: ($0.1M) (+96.9%).

Cara Therapeutics (NASDAQ:CARA) +16.7% premarket after announcing positive results from a human abuse liability trial of its peripheral Opioid for acute pain, an intravenous formulation of CR845.Top-line results showed that therapeutic and supratherapeutic doses of I.V. CR845 met the trial's primary endpoint by demonstrating highly statistically significant lower "drug liking" scores.




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BMR:1